Previous 10 | Next 10 |
2023-07-11 17:08:02 ET Gainers: Incyte ( NASDAQ: INCY ) +4% . Veracyte ( VCYT ) +4% . Kronos ( KRON ) +3% . Applied Optoelectronics ( AAOI ) +3% . GoodRx ( GDRX ) +3% . Losers: Silk Road ( SI...
Phase 3 TruE-AD3 Study met its primary endpoint Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura ® ) in children (age ≥...
2023-07-10 11:17:31 ET Summary Incyte Corporation's Q1 2023 financial performance showed mixed results, with a 10% rise in GAAP revenues but a significant drop in operating and net income. Despite a 23% stock decline over the past six months, Incyte demonstrated impressive growth ...
Opzelura ® is the first approved treatment in the United Kingdom (UK) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with ruxolitinib cream resulted in improved facial and total body repigmentation, sustained and contin...
2023-06-29 05:02:34 ET For further details see: Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent
2023-06-23 04:59:05 ET Goldman Sachs has rebalanced its ROE Growth basket of 50 stocks selected based on consensus expected return-on-equity growth over the next 12 months. The sector-neutral basket tapped 25 names in the rebalance. The median stock in the basket is projected to ach...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the European Hematology Association 2023 (EHA2023) Hyb...
2023-05-19 11:27:29 ET BofA Securities has initiated Xencor ( NASDAQ: XNCR ) with a buy highlighting its pipeline of protein therapeutics for cancer and inflammatory diseases. The firm has a $42 price target (~61% upside based on Thursday's close) in Friday morning trading. ...
Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective Jun...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...